Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $9.0052W HIGH $17.45
Volume
102.31 K
Value Traded
1.30 M
Short % Float
2.38%
+4.49%Week
-34.86%1 Month
-26.24%3 Month
-12.86%6 Month
-20.96%5 Year
-20.96%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
447.17 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
425.11 M
Total Shares
49.25 M
Float Shares
36.45 M
Insiders
25.98%
Institutions
26.72%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
AGMB Catalyst Timeline
Dated clinical, regulatory and corporate events for AgomAb Therapeutics NV
Catalyst Timeline
Dated clinical, regulatory & corporate events for AgomAb Therapeutics NV
34Total events
9Upcoming
7Tier-1 (high impact)
2026 to 2027Coverage
Upcoming catalysts 2
Event history 15
▲Safety Data UpdateOntunisertibClinical Data
Favorable long-term safety and tolerability profile maintained through up to 60 weeks in OLE
Fibrostenosing Crohn's Diseasesource ↗
▲Additional DataOntunisertibClinical Data
MRE assessments at Weeks 24 and 48 suggest radiological stabilization of fibrotic strictures
Fibrostenosing Crohn's Diseasesource ↗
▲Biomarker DataOntunisertibClinical Data
Radiological stabilization of fibrotic strictures suggested at Weeks 24 and 48
Fibrostenosing Crohn's Diseasesource ↗
▲Topline ReadoutOntunisertibClinical Data
Positive topline results from 48-week OLE portion of Phase 2a STENOVA trial
Fibrostenosing Crohn's Diseasesource ↗
▲PK PD DataOntunisertibClinical Data
Systemic exposure remained low and consistent with Part A observations
Fibrostenosing Crohn's Diseasesource ↗
●R&D DayPresentation
Company webcast on October 1, 2026 at 8:30 a.m. ET to discuss STENOVA OLE results
▲Topline ReadoutAGMB-447Clinical Data
Positive Phase 1 topline results of AGMB-447 in IPF patients
Idiopathic Pulmonary Fibrosissource ↗
▲Safety Data UpdateAGMB-447Clinical Data
AGMB-447 Phase 1 safety/tolerability profile in IPF patients
Idiopathic Pulmonary Fibrosissource ↗
▲PK PD DataAGMB-447Clinical Data
AGMB-447 Phase 1 PK/target engagement data in IPF patients
Idiopathic Pulmonary Fibrosissource ↗
▲Corporate ApprovalCorporate
Shareholders approved all resolutions at Special and Extraordinary General Shareholders' Meeting, including appointment of Marino Garcia and Dr. Naimish Patel to Board
●Management ChangeCorporate
Appointment of Marino Garcia and Dr. Naimish Patel as non-executive members of the Board of Directors
●Trial Authorization (CTA / IND)AGMB-447Ex-US Regulatory
Clinical Trial Application submitted for INSPIRIA Phase 2 study of AGMB-447 in IPF
Idiopathic Pulmonary Fibrosissource ↗
▲FDA Feedback ReceivedOntunisertibFDA Meeting
FDA alignment on key elements of NOV-ERA Phase 2b study design
Fibrostenosing Crohn’s Disease (FSCD)source ↗
Past FDA Catalysts and PDUFA Decisions
How AGMB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-01-01 | AGMB-447 | Phase 1 interim results | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D34 / 100
Pipeline Score
$184M
Pipeline Value
Overvalued
Valuation Signal
4
Drugs Scored
0.4x
rNPV / MCap
Top 58%
Micro Cap(rank 383 of 660)
Percentile Rank
AgomAb Therapeutics NV faces pipeline headwinds (34/100), with $769M risk-adjusted pipeline value, led by AGMB-129 in Fibrostenotic Crohn's Disease (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AGMB-129 Small moleculeCompletedNCT07118878 | Fibrostenotic Crohn's Disease | Phase 2 | COMPLETED | 133 | Sep 15, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every AGMB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ontunisertib Fast Track | Fibrostenosing Crohn's disease | Phase 2a | 2026-10-01 | Low annualized FSCD-related event rate of 3%; Sustained disease control observed across symptoms and disease activity scores; Favorable safety and tolerability profile maintained through up to 60 weeks of treatmentRead More | Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's DiseaseRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Epstein David RDirector | Buy | 5,000 15,000 held | $8.90 | 10/08/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AGMB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 0.6 % | 21.54 M | 2.05 M |
AGMB Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AGMB ranks across every disease it competes in
Competitive Position is a premium feature
See how AGMB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAGMB News
AGMB▲ +0.4%today
Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation
Agomab Therapeutics announced that the Open-Label Extension data from the Phase 2a STENOVA study of ontunisertib will be presented at UEG Week 2026. The results support the launch of a global Phase 2b study, NOV-ERA, aimed at treating Fibrostenosing Crohn's disease. Additionally, Agomab will host a symposium discussing fibro-inflammation's role in inflammatory bowel disease.
Read more →AGMB▼ -22.1%on this news
Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease
Agomab Therapeutics announced positive topline results from the open-label extension study of ontunisertib in patients with Fibrostenosing Crohn's disease. The study showed a favorable safety profile and low event rate, with sustained disease control over 60 weeks. These findings support the upcoming global NOV-ERA Phase 2b study aimed at further evaluating ontunisertib's efficacy.
Read more →AGMBAgomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study
Agomab Therapeutics announced positive Phase 1 results for AGMB-447, an inhaled treatment for Idiopathic Pulmonary Fibrosis (IPF). The study demonstrated a favorable safety profile and effective target engagement in patients. The company has submitted a Clinical Trial Application for the Phase 2 INSPIRIA study, which aims to evaluate AGMB-447's efficacy and safety in a larger patient population. The study is expected to commence before the end of 2026.
Read more →AGMB▼ -6%on this newsshared move
Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
Agomab Therapeutics announced the appointment of Marino Garcia and Dr. Naimish Patel to its Board of Directors, following shareholder approval at a special meeting. Both appointees bring extensive experience that will aid Agomab's mission to develop therapies for fibro-inflammatory diseases. The company also approved a consolidation and split adjustment of pre-IPO warrants.
Read more →AGMB▲ +6.4%on this news
Agomab to Participate in Upcoming Investor Conferences
Agomab Therapeutics NV has announced its participation in several upcoming investor conferences in September 2026. The management team will engage in discussions at notable events including Citi's Biopharma Conference and the H.C. Wainwright Global Investment Conference. Agomab is dedicated to developing therapies for fibro-inflammatory diseases, emphasizing their commitment to addressing significant medical needs.
Read more →AGMBAgomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
Agomab Therapeutics NV has proposed the appointments of Marino Garcia and Dr. Naimish Patel to its Board of Directors. This move reflects the company's commitment to strengthening its leadership team as it focuses on fibro-inflammatory diseases. The new appointments are expected to bring valuable expertise to the board.
Read more →AGMB▲ +7.4%on this newsshared move
Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook
Agomab has reported its financial results for the first half of 2026, highlighting a significant regulatory alignment with the FDA regarding the NOV-ERA Phase 2b study design for Ontunisertib in Fibrostenosing Crohn’s Disease. The study features a novel primary endpoint focused on endoscopic passability. Additionally, topline data from an open-label long-term extension study was shared, indicating promising outcomes.
Read more →AGMB▲ +6.2%on this news· ran to +49% by day 3
Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease
Agomab Therapeutics has announced the design of its Phase 2b NOV-ERA study for ontunisertib, aimed at treating Fibrostenosing Crohn's Disease. The study has received regulatory alignment from the FDA on key design elements, including a novel primary endpoint. The company expects to begin dosing participants in the second half of 2026.
Read more →AGMB▲ +5.6%on this news
Agomab Announces Results of Annual General Meeting
Agomab Therapeutics NV announced the successful outcomes of its Annual General Meeting held on May 26, 2026. All agenda items, including the approval of financial statements and reappointments of board members, were approved. The company continues to focus on developing therapies for fibro-inflammatory diseases.
Read more →AGMBAgomab to Participate in Upcoming Conferences
Agomab Therapeutics NV has announced its participation in several upcoming industry and investor conferences. Key presentations will include a poster on AGMB-447, which targets idiopathic pulmonary fibrosis, and fireside chats at major investor events. These engagements aim to showcase Agomab's advancements in fibro-inflammation treatments.
Read more →AGMBAgomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
Agomab Therapeutics NV has reported its financial results for the year ending December 31, 2025, showing an operating loss of $59.3 million and a net loss of $62.5 million. The company raised $208 million through its IPO, which is expected to extend its cash runway into the first half of 2029. Progress in clinical trials was noted, with positive FDA interactions and plans to initiate Phase 2 studies for Ontunisertib and AGMB-447 in 2026. The company remains focused on achieving key clinical milestones and advancing its innovative therapies for fibro-inflammatory diseases.
Read more →AGMB▼ -7.7%on this news· ran to -18% by day 3
Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis
Agomab Therapeutics has been granted a U.S. patent for AGMB-447, an inhaled small molecule inhibitor aimed at treating Idiopathic Pulmonary Fibrosis (IPF). This patent secures intellectual property rights for AGMB-447 until at least 2041. The drug is currently undergoing a Phase 1b study, with results expected later this year. Agomab emphasizes the potential of AGMB-447 to meet significant medical needs in IPF.
Read more →AGMBAgomab Announces Closing of Initial Public Offering
Agomab Therapeutics NV has successfully closed its initial public offering, raising approximately $200 million by offering 12.5 million American Depositary Shares at $16.00 each. The shares began trading on the Nasdaq Global Select Market under the ticker AGMB on February 6, 2026. The company is focused on developing therapies for chronic fibrotic diseases, addressing significant unmet medical needs.
Read more →AGMBAgomab Announces Pricing of Initial Public Offering
Agomab Therapeutics NV has announced the pricing of its initial public offering, aiming to raise $200 million by offering 12.5 million American Depositary Shares at $16.00 each. The shares are set to begin trading on the Nasdaq Global Select Market on February 6, 2026. The offering is expected to close on February 9, 2026, pending customary conditions.
Read more →AGMBAgomab Announces Launch of Initial Public Offering
Agomab Therapeutics NV has announced the launch of an initial public offering (IPO) of 12,500,000 American Depositary Shares (ADSs), each representing one common share. The expected price range for the ADSs is between $15.00 and $17.00, and the company anticipates granting underwriters the option to purchase an additional 1,875,000 ADSs. Agomab, focused on developing novel therapies for chronic fibrotic diseases, has applied for listing on the Nasdaq Global Select Market under the ticker symbol 'AGMB'.
Read more →AGMBAgomab Announces Positive Phase 1 Interim Results with AGMB-447 in Healthy Participants and Initiation of Idiopathic Pulmonary Fibrosis Cohort
Agomab Therapeutics has reported positive interim results from its Phase 1 study of AGMB-447, an inhaled small molecule inhibitor targeting ALK5 for the treatment of Idiopathic Pulmonary Fibrosis. The study involved healthy participants and marks a significant step in Agomab's clinical development. The company is now initiating a cohort specifically for Idiopathic Pulmonary Fibrosis.
Read more →AGMBAgomab Announces Positive Topline Phase 2a Data for Ontunisertib in Fibrostenosing Crohn’s Disease
Agomab Therapeutics has reported positive topline results from its Phase 2a clinical trial of ontunisertib, an oral small molecule inhibitor targeting ALK5, for treating Fibrostenosing Crohn's Disease. The trial involved 103 participants who completed 12 weeks of treatment, indicating potential efficacy in this challenging condition.
Read more →AGMBLate-Breaking Interim STENOVA Data for AGMB-129 in Fibrostenosing Crohn’s to be Presented at Digestive Disease Week® 2025
Agomab Therapeutics announced that interim data from the STENOVA1 Phase 2a clinical trial of AGMB-129 will be presented at Digestive Disease Week 2025. AGMB-129 is an oral small molecule inhibitor targeting ALK5 for Fibrostenosing Crohn's Disease. The presentation is scheduled for May 3-6, 2025, in San Diego.
Read more →AGMBAgomab Announces Positive Topline Phase 2a Interim Results for AGMB-129 in Fibrostenosing Crohn’s Disease
Agomab has announced positive interim results from its Phase 2a trial of AGMB-129 for fibrostenosing Crohn's disease. The treatment successfully met all primary and secondary endpoints after 12 weeks in a study involving 44 patients. Detailed results will be shared at an upcoming scientific conference, with full results expected in Q4 2025.
Read more →About AgomAb Therapeutics NV
BIOPHARMAWATCH ELITE PLUS
Trade the next AGMB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime